Table 3.
Clinical characteristics, cardiorespiratory fitness, and biomarkers in patients with and without injection site reactions.
| Patients with Injection Site Reactions (N = 8) | Patients without Injection Site Reactions (N = 56) | p Value | |
|---|---|---|---|
| Variables | |||
| Age (years) | 51 [45–59] | 55 [52–64] | 0.10 |
| Sex—F (%)/M (%) | 4 (50)/4 (50) | 28 (50)/28 (50) | 1.00 |
| Race—Black (%)/White (%) | 4 (50)/4 (50) | 393 (70)/17 (30) | 0.11 |
| BMI (kg/m2) | 36 [35–41] | 38 [32–45] | 0.45 |
| NYHA class | |||
| NYHA class II | 4 (50) | 20 (36) | 0.43 |
| NYHA class III | 4 (50) | 36 (64) | 0.43 |
| CAD | 2 (25) | 13 (23) | 0.91 |
| DM | 6 (75) | 32 (57) | 0.34 |
| HTN | 6 (75) | 52 (93) | 0.11 |
| HLP | 4 (50) | 41 (73) | 0.18 |
| ACEi/ARB | 7 (88) | 42 (75) | 0.44 |
| Beta-blocker | 8 (100) | 49 (88) | 0.29 |
| MRA | 6 (75) | 24 (43) | 0.09 |
| CPX | |||
| Peak VO2 (mLO2·kg−1·min−1) | |||
| - Baseline | 16.8 [13.2–19.4] | 14.0 [11.6–16.5] | 0.16 |
| - On-treatment | 18.5 [14.5–25.2] | 14.9 [12.3–17.2] | 0.044 |
| - Off-treatment | 15.0 [13.7–25.5] | 14.8 [11.4–17.5] | 0.19 |
| - Delta baseline-on treatment | 3.0 [0.9–4.3] | 0.3 [−0.6–1.8] | 0.015 |
| - Delta on-off treatment | −1.5 [−2.1–0.7] | −0.3 [−2.1–0.6] | 0.62 |
| Exercise time (seconds) | |||
| - Baseline | 595 [505–725] | 455 [290–548] | 0.007 |
| - On-treatment | 650 [490–830] | 500 [370–583] | 0.016 |
| - Off-treatment | 730 [580–870] | 510 [375–630] | 0.026 |
| Biomarkers | |||
| CRP (mg/L) | |||
| - Baseline | 2.8 [2.3–13.3] | 6.5 [3.6–15.5] | 0.12 |
| - On-treatment | 1.3 [0.5–7.2] | 1.4 [0.9–3.7] | 0.81 |
| - Off-treatment | 2.1 [0.6–9.7] | 6.8 [2.9–13.6] | 0.11 |
| NT-proBNP (pg/mL) | |||
| - Baseline | 74 [13–219] | 634 [200–1774] | 0.002 |
| - On-treatment | 81 [13–120] | 445 [95–1187] | 0.003 |
| - Off-treatment | 57 [20–120] | 383 [121–1094] | 0.001 |
| WBC (×103 cells/µL) | |||
| - Baseline | 6.1 [5.2–7.8] | 6.6 [5.6–8.3] | 0.50 |
| - On-treatment | 6.1 [4.4–7.4] | 5.6 [4.5–6.7] | 0.44 |
| - Off-treatment | 6.2 [5.4–7.3] | 6.9 [5.4–8.3] | 0.48 |
| Neutrophils (×103 cells/µL) | |||
| - Baseline | 3.5 [2.5–5.1] | 4.4 [3.2–5.7] | 0.27 |
| - On-treatment | 2.9 [1.9–5.1] | 2.9 [2.0–4.0] | 0.75 |
| - Off-treatment | 3.7 [2.7–4.3] | 4.4 [3.1–5.7] | 0.34 |
| Eosinophils (×103 cells/µL) | |||
| - Baseline | 0.3 [0.1–0.4] | 0.2 [0.1–0.3] | 0.21 |
| - On-treatment | 0.5 [0.3–0.6] | 0.2 [0.1–0.4] | 0.023 |
| - Off-treatment | 0.2 [0.2–0.4] | 0.2 [0.1–0.3] | 0.34 |
Data are expressed as median [interquartile range] or number (%). Abbreviations: F, female; M, male; AA, African-American; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; HTN, hypertension; HLP, hyperlipidemia; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blockade; MRA, mineralocorticoid receptor antagonist; LVEF, left ventricular ejection fraction; CPX, cardiopulmonary exercise test; VO2, oxygen consumption; CRP, C-reactive protein; NT-proBNP, N-terminal pro b-type natriuretic peptide.